Your session is about to expire
← Back to Search
IgE Threshold Testing for Food Allergy
Phase 2
Recruiting
Led By Fernanda D Young, M.D.
Research Sponsored by National Institute of Allergy and Infectious Diseases (NIAID)
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Aged 3-21 years.
Be younger than 65 years old
Must not have
Known cardiac disease.
Any chronic medical condition requiring long-term use of oral steroids.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up oral food challenge visits
Summary
This trial is testing whether people with atopic dermatitis are truly allergic to milk and/or peanuts.
Who is the study for?
This trial is for children and young adults aged 3-21 with atopic dermatitis (eczema) who may have milk or peanut allergies, a high total IgE level, and are part of another NIH study. They must be willing to stop certain allergy medications before food challenges.
What is being tested?
The trial tests if participants with eczema are truly allergic to milk or peanuts by giving them increasing amounts of these foods or placebos in controlled settings. The goal is to improve food allergy testing methods.
What are the potential side effects?
Potential side effects include allergic reactions during the oral food challenge, ranging from mild symptoms like itching to more severe reactions that could require medical intervention.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am between 3 and 21 years old.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I have a known heart condition.
Select...
I am on long-term oral steroids for a chronic condition.
Select...
I am currently taking a beta-blocker medication.
Select...
I have a genetic condition that increases my IgE levels or affects severe allergic reactions.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ oral food challenge visitsv
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~oral food challenge visitsv
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Allergy to milk and peanut status; allowing for estimation of IgE thresholds that determine a subgroup with at least 50% chance of tolerance in patients with elevated total serum IgE levels and history of AD.
Secondary study objectives
Basophil and mast cell reactivity and other exploratory markers.
Trial Design
4Treatment groups
Experimental Treatment
Group I: Two-Step Open FeedingExperimental Treatment4 Interventions
Participants who consume baked milk, straight milk, and/or peanut products less than once per week but at least once per month will do a two step open oral food challenge.
Group II: Peanut DBPCFCExperimental Treatment2 Interventions
The DBPCFC for peanut allergy will be done with either peanut flour or a placebo (oat flour). The following participants will undergo this DBPCFC: - All participants who eat peanut less than once per month - Participants who never eat peanut On the first day of this challenge, participants will be randomized to either peanut or placebo, and then will be challenged with the other food on the next day.
Group III: One-Step Open FeedingExperimental Treatment4 Interventions
Participants who are consuming baked milk, straight milk, and/or peanut products at least once per week will do a one-step oral food challenge.
Group IV: Milk DBPCFCExperimental Treatment2 Interventions
There are two double blind placebo controlled food challenges. The first challenge is to baked milk. The following participants will undergo this DBPCFC: - All participants who eat baked milk less than once per month. - Participants who never eat baked milk or straight milk. On the first day of this challenge, participants will be randomized to either milk Baked milk or rice milk. Dry milk powder or corn starch. or placebo, and then will be challenged with the other food on the next day.
Find a Location
Who is running the clinical trial?
National Institute of Allergy and Infectious Diseases (NIAID)Lead Sponsor
3,336 Previous Clinical Trials
5,382,634 Total Patients Enrolled
12 Trials studying Food Allergy
12,456 Patients Enrolled for Food Allergy
National Institutes of Health Clinical Center (CC)NIH
389 Previous Clinical Trials
30,879,536 Total Patients Enrolled
Fernanda D Young, M.D.Principal InvestigatorNational Institute of Allergy and Infectious Diseases (NIAID)
Pamela A Guerrerio, M.D.Principal InvestigatorNational Institute of Allergy and Infectious Diseases (NIAID)
4 Previous Clinical Trials
3,589 Total Patients Enrolled
1 Trials studying Food Allergy
1,800 Patients Enrolled for Food Allergy
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- You have been diagnosed with Alzheimer's disease by a doctor or you have reported having symptoms of Alzheimer's disease.I have a known heart condition.I am willing to have genetic tests done on my blood.I am willing to try a food challenge with a placebo and the test food.Your blood test shows that you have very high IgE levels.I am on long-term oral steroids for a chronic condition.I am currently taking a beta-blocker medication.I am willing to stop taking certain allergy medications before a food test.I have used omalizumab or dupilumab in the last 6 months.I am between 3 and 21 years old.I have a genetic condition that increases my IgE levels or affects severe allergic reactions.I have an active eosinophilic GI disorder but am symptom-free due to treatment or my diet.
Research Study Groups:
This trial has the following groups:- Group 1: Milk DBPCFC
- Group 2: One-Step Open Feeding
- Group 3: Two-Step Open Feeding
- Group 4: Peanut DBPCFC
Awards:
This trial has 0 awards, including:Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.